L N van Steenbergen1, M A G Elferink2, P Krijnen3, V E P P Lemmens4, S Siesling5, H J T Rutten6, D J Richel7, H E Karim-Kos8, J W W Coebergh4. 1. Department of Research, Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Eindhoven. Electronic address: research@ikz.nl. 2. Department of Research, Comprehensive Cancer Centre North East, Enschede/Groningen. 3. Comprehensive Cancer Centre West, Leiden. 4. Department of Research, Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Eindhoven; Department of Public Health, Erasmus MC University Medical Centre, Rotterdam. 5. Department of Research, Comprehensive Cancer Centre North East, Enschede/Groningen; Department of Health Technology and Services Research, Twente University, Enschede. 6. Department of Surgery, Catharina Hospital, Eindhoven. 7. Department of Internal Medicine, Academic Medical Centre Amsterdam, The Netherlands. 8. Department of Public Health, Erasmus MC University Medical Centre, Rotterdam.
Abstract
BACKGROUND: We described changes in treatment of colon cancer over time and the impact on survival in The Netherlands in the period 1989-2006. PATIENTS AND METHODS: All 103,744 patients with invasive colon cancer during 1989-2006 in The Netherlands were included. Data were extracted from The Netherlands Cancer Registry. Trends in treatment over time were analysed and multivariable relative survival analysis was carried out. RESULTS: The administration of adjuvant chemotherapy in stage III patients <75 years increased from 19% in 1989-1993 to 79% in 2004-2006 and from 1% to 19% in stage III patients ≥75 years. Among stage IV patients, resection rates of the primary tumour decreased from 72% to 63%, while chemotherapy administration increased from 23% to 64% in those <75 years. Survival increased from 52% to 58% in males and from 55% to 58% among females. Stage III patients with adjuvant chemotherapy exhibited a relative excess risk of 0.4 (95% confidence interval 0.4-0.4) compared with those without. Among stage IV patients, resection of primary tumour, palliative chemotherapy, and metastasectomy were important prognostic factors. CONCLUSIONS: There were substantial improvements in management and survival of colon cancer from 1989 to 2006. Stage III disease patients with colon cancer experienced the largest improvement in survival, most likely related to the increased administration of adjuvant chemotherapy.
BACKGROUND: We described changes in treatment of colon cancer over time and the impact on survival in The Netherlands in the period 1989-2006. PATIENTS AND METHODS: All 103,744 patients with invasive colon cancer during 1989-2006 in The Netherlands were included. Data were extracted from The Netherlands Cancer Registry. Trends in treatment over time were analysed and multivariable relative survival analysis was carried out. RESULTS: The administration of adjuvant chemotherapy in stage III patients <75 years increased from 19% in 1989-1993 to 79% in 2004-2006 and from 1% to 19% in stage III patients ≥75 years. Among stage IV patients, resection rates of the primary tumour decreased from 72% to 63%, while chemotherapy administration increased from 23% to 64% in those <75 years. Survival increased from 52% to 58% in males and from 55% to 58% among females. Stage III patients with adjuvant chemotherapy exhibited a relative excess risk of 0.4 (95% confidence interval 0.4-0.4) compared with those without. Among stage IV patients, resection of primary tumour, palliative chemotherapy, and metastasectomy were important prognostic factors. CONCLUSIONS: There were substantial improvements in management and survival of colon cancer from 1989 to 2006. Stage III disease patients with colon cancer experienced the largest improvement in survival, most likely related to the increased administration of adjuvant chemotherapy.
Authors: L Tilson; L Sharp; C Usher; C Walsh; Whyte S; A O'Ceilleachair; C Stuart; B Mehigan; M John Kennedy; P Tappenden; J Chilcott; A Staines; H Comber; M Barry Journal: Eur J Health Econ Date: 2011-06-03
Authors: Arantza Fariña Sarasqueta; Eliane C M Zeestraten; Tom van Wezel; Gesina van Lijnschoten; Ronald van Eijk; Jan Willem T Dekker; Peter J K Kuppen; Ines J Goossens-Beumer; Valery E P P Lemmens; Cornelis J H van de Velde; Harm J T Rutten; Hans Morreau; A J C van den Brule Journal: Cell Oncol (Dordr) Date: 2011-08-10 Impact factor: 6.730
Authors: Takumu Hasebe; Jun Matsukawa; Daina Ringus; Jun Miyoshi; John Hart; Atsushi Kaneko; Masahiro Yamamoto; Toru Kono; Mikihiro Fujiya; Yutaka Kohgo; Chong-Zi Wang; Chun-Su Yuan; Marc Bissonnette; Mark W Musch; Eugene B Chang Journal: Phytother Res Date: 2016-10-12 Impact factor: 5.878
Authors: Lydia G M van der Geest; Jorine't Lam-Boer; Miriam Koopman; Cees Verhoef; Marloes A G Elferink; Johannes H W de Wilt Journal: Clin Exp Metastasis Date: 2015-04-22 Impact factor: 5.150
Authors: Avinash Sharma; Olusegun I Alatise; Adewale O Adisa; Olukayode A Arowolo; Olalekan Olasehinde; Olusola C Famurewa; Adeleye D Omisore; A O Komolafe; O Olaofe; Aba I Katung; Ayoola D Ibikunle; Ayoola A Egberongbe; Samuel A Olatoke; S O Agodirin; A O Adesiyun; Ademola Adeyeye; K Ibrahim; O A Kolawole; O L Idris; M O Adejumobi; Adebowale I Ajayi; Akinwumi O Olakanmi; Jeremy C Constable; Ken Seier; Mithat Gonen; Murray F Brennan; T Peter Kingham Journal: J Surg Oncol Date: 2019-11-19 Impact factor: 3.454
Authors: Eric P van der Stok; Manon C W Spaander; Dirk J Grünhagen; Cornelis Verhoef; Ernst J Kuipers Journal: Nat Rev Clin Oncol Date: 2016-12-20 Impact factor: 66.675
Authors: Gabriela M Vargas; Kristin M Sheffield; Abhishek D Parmar; Yimei Han; Aakash Gajjar; Kimberly M Brown; Taylor S Riall Journal: J Gastrointest Surg Date: 2014-02 Impact factor: 3.452